ES2914876T3 - Procesos para la preparación de (S)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2, 6-diona y formas farmacéuticas aceptables de las mismas - Google Patents

Procesos para la preparación de (S)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2, 6-diona y formas farmacéuticas aceptables de las mismas Download PDF

Info

Publication number
ES2914876T3
ES2914876T3 ES18206764T ES18206764T ES2914876T3 ES 2914876 T3 ES2914876 T3 ES 2914876T3 ES 18206764 T ES18206764 T ES 18206764T ES 18206764 T ES18206764 T ES 18206764T ES 2914876 T3 ES2914876 T3 ES 2914876T3
Authority
ES
Spain
Prior art keywords
compound
formula
benzyl
acid
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18206764T
Other languages
English (en)
Spanish (es)
Inventor
John Fitzgerald Traverse
Chengmin Zhang
Gregg B Feigelson
Benjamin M Cohen
William Wei-Hwa Leong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Application granted granted Critical
Publication of ES2914876T3 publication Critical patent/ES2914876T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES18206764T 2012-08-09 2013-08-08 Procesos para la preparación de (S)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2, 6-diona y formas farmacéuticas aceptables de las mismas Active ES2914876T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261681477P 2012-08-09 2012-08-09

Publications (1)

Publication Number Publication Date
ES2914876T3 true ES2914876T3 (es) 2022-06-17

Family

ID=49035933

Family Applications (2)

Application Number Title Priority Date Filing Date
ES18206764T Active ES2914876T3 (es) 2012-08-09 2013-08-08 Procesos para la preparación de (S)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2, 6-diona y formas farmacéuticas aceptables de las mismas
ES13753229T Active ES2712652T3 (es) 2012-08-09 2013-08-08 Procesos para la preparación de (S)-3-4-((4-(morfolinometil) bencil) oxi) -1-oxoisoindolin-2il-) piperidin-2, 6-diona y formas farmacéuticas aceptables de las mismas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES13753229T Active ES2712652T3 (es) 2012-08-09 2013-08-08 Procesos para la preparación de (S)-3-4-((4-(morfolinometil) bencil) oxi) -1-oxoisoindolin-2il-) piperidin-2, 6-diona y formas farmacéuticas aceptables de las mismas

Country Status (19)

Country Link
US (2) US9309220B2 (enExample)
EP (2) EP3466942B1 (enExample)
JP (1) JP6444866B2 (enExample)
KR (1) KR20150041650A (enExample)
CN (1) CN104718202B (enExample)
AU (1) AU2013299559B2 (enExample)
BR (1) BR112015002183A2 (enExample)
CA (2) CA2879151C (enExample)
CR (1) CR20150051A (enExample)
EC (1) ECSP15004585A (enExample)
ES (2) ES2914876T3 (enExample)
HK (1) HK1211577A1 (enExample)
IL (1) IL236925A0 (enExample)
IN (1) IN2015DN00845A (enExample)
MX (2) MX2015001633A (enExample)
PH (1) PH12015500214A1 (enExample)
RU (1) RU2015108057A (enExample)
SG (1) SG11201500984QA (enExample)
WO (1) WO2014025978A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3202460T1 (sl) 2010-02-11 2019-10-30 Celgene Corp Arilmetoksi izoindolin derivati in sestavki, ki jih obsegajo in metode za uporabo le-teh
WO2012135299A1 (en) 2011-03-28 2012-10-04 Deuteria Pharmaceuticals Inc 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
JP6359563B2 (ja) 2013-01-14 2018-07-18 デュートルクス・リミテッド・ライアビリティ・カンパニーDeuteRx, LLC 3−(5置換−4−オキソキナゾリン−3(4h)−イル)−3−ジュウテロピペリジン−2,6−ジオン誘導体
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
CA2941560A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
MX2020002010A (es) 2017-08-21 2020-07-13 Celgene Corp Procesos para la preparacion de 4,5-diamino-5-oxopentanoato de (s)-terc-butilo.
US11529339B2 (en) 2018-10-01 2022-12-20 Celgene Corporation Combination therapy for the treatment of cancer
CN110194760B (zh) * 2019-05-27 2021-08-17 浙江农林大学暨阳学院 制备3-亚苄基-2-(7’-喹啉)-2,3-二氢-异吲哚-1-酮类化合物的方法
IL293478A (en) * 2019-12-02 2022-08-01 Celgene Corp Treatment for cancer
CN113896711A (zh) 2020-07-06 2022-01-07 北京诺诚健华医药科技有限公司 杂环类免疫调节剂
WO2024064646A1 (en) * 2022-09-20 2024-03-28 Celgene Corporation Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same
WO2024212883A1 (zh) * 2023-04-11 2024-10-17 上海科胜药物研发有限公司 一种芳基甲氧基异吲哚啉衍生物的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
CA2579291C (en) * 2004-09-03 2011-11-29 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
SI2380887T1 (sl) * 2005-06-30 2013-12-31 Celgene Corporation Postopki priprave spojin 4-amino-2-/2,6-dioksopiperidin-3-il)izoindolin -1,3-diona
US8153659B2 (en) 2007-03-20 2012-04-10 Celgene Corporation 4′-O-substituted isoindoline derivatives and compositions comprising and methods of using the same
SI3202460T1 (sl) 2010-02-11 2019-10-30 Celgene Corp Arilmetoksi izoindolin derivati in sestavki, ki jih obsegajo in metode za uporabo le-teh
KR20130038232A (ko) 2010-03-08 2013-04-17 낫코 파마 리미티드 무수 레날리도마이드 form-i
JP6185490B2 (ja) 2012-02-21 2017-08-23 セルジーン コーポレイション 3−(4−ニトロ−1−オキソイソインドリン−2−イル)ピペリジン−2,6−ジオンの固体形態

Also Published As

Publication number Publication date
CA2879151A1 (en) 2014-02-13
SG11201500984QA (en) 2015-04-29
HK1211577A1 (en) 2016-05-27
EP3466942B1 (en) 2022-04-20
CR20150051A (es) 2015-05-11
PH12015500214A1 (en) 2015-04-27
AU2013299559B2 (en) 2017-08-17
MX385058B (es) 2025-03-14
MX2015001633A (es) 2015-04-08
EP2882736A1 (en) 2015-06-17
IN2015DN00845A (enExample) 2015-06-12
AU2013299559A1 (en) 2015-02-05
EP2882736B1 (en) 2019-01-09
US20160251333A1 (en) 2016-09-01
RU2015108057A (ru) 2016-09-27
BR112015002183A2 (pt) 2017-07-04
WO2014025978A1 (en) 2014-02-13
CA2879151C (en) 2021-03-30
CN104718202A (zh) 2015-06-17
ECSP15004585A (es) 2015-12-31
US9975872B2 (en) 2018-05-22
KR20150041650A (ko) 2015-04-16
CN104718202B (zh) 2018-11-20
US20140046058A1 (en) 2014-02-13
CA3108974C (en) 2023-04-04
JP2015524481A (ja) 2015-08-24
JP6444866B2 (ja) 2018-12-26
CA3108974A1 (en) 2014-02-13
US9309220B2 (en) 2016-04-12
IL236925A0 (en) 2015-03-31
ES2712652T3 (es) 2019-05-14
EP3466942A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
ES2914876T3 (es) Procesos para la preparación de (S)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2, 6-diona y formas farmacéuticas aceptables de las mismas
JP7579253B2 (ja) 甲状腺ホルモン受容体ベータアゴニスト化合物
CN114174281B (zh) 细胞周期蛋白依赖性激酶7(cdk7)的降解剂及其用途
CA2632194A1 (en) N4-phenyl-quinazoline-4-amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
CA3142069A1 (en) Aurora kinase inhibitor and use thereof
JP5892550B2 (ja) 縮合イミダゾール誘導体
WO2014017938A2 (en) Process for the synthesis of substituted urea compounds
ES2641258T3 (es) Compuesto heterocíclico bicíclico
JP2016522240A (ja) RORcモジュレーターとしてのアリールスルタム誘導体
JP5372138B2 (ja) 新規ベンゾオキサジンベンズイミダゾール誘導体、これを含む薬学組成物およびこの用途
CA2856824A1 (en) Cyclic urea derivatives as androgen receptor antagonists
US11453657B2 (en) Compounds for the treatment of parasitic infections
EA015152B1 (ru) О-замещенные производные дибензилмочевины в качестве антагонистов рецепторов trpv1